MA26826A1 - Combinaisons synergiques d'un antagoniste recepteur de nk1 et d'un analogue structurel de gaba. - Google Patents

Combinaisons synergiques d'un antagoniste recepteur de nk1 et d'un analogue structurel de gaba.

Info

Publication number
MA26826A1
MA26826A1 MA26587A MA26587A MA26826A1 MA 26826 A1 MA26826 A1 MA 26826A1 MA 26587 A MA26587 A MA 26587A MA 26587 A MA26587 A MA 26587A MA 26826 A1 MA26826 A1 MA 26826A1
Authority
MA
Morocco
Prior art keywords
receptor antagonist
synergistic combinations
structural analog
gaba
gaba structural
Prior art date
Application number
MA26587A
Other languages
English (en)
Inventor
Lakhbir Singh
John Hughes
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA26826A1 publication Critical patent/MA26826A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA26587A 1999-10-07 2002-04-05 Combinaisons synergiques d'un antagoniste recepteur de nk1 et d'un analogue structurel de gaba. MA26826A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
MA26826A1 true MA26826A1 (fr) 2004-12-20

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26587A MA26826A1 (fr) 1999-10-07 2002-04-05 Combinaisons synergiques d'un antagoniste recepteur de nk1 et d'un analogue structurel de gaba.

Country Status (38)

Country Link
EP (2) EP1221950B1 (fr)
JP (2) JP2003510356A (fr)
KR (1) KR20020060192A (fr)
CN (1) CN1387434A (fr)
AP (1) AP2002002501A0 (fr)
AR (1) AR029646A1 (fr)
AT (1) ATE269072T1 (fr)
AU (2) AU7663300A (fr)
BG (1) BG106548A (fr)
BR (1) BR0014598A (fr)
CA (1) CA2385930A1 (fr)
CO (1) CO5280195A1 (fr)
CR (1) CR6614A (fr)
CZ (1) CZ20021116A3 (fr)
DE (1) DE60011650T2 (fr)
DK (1) DK1221950T3 (fr)
EA (1) EA004266B1 (fr)
EE (1) EE200200185A (fr)
ES (1) ES2220542T3 (fr)
GT (1) GT200000166A (fr)
HR (1) HRP20020286A2 (fr)
HU (1) HUP0203466A3 (fr)
IL (1) IL148965A0 (fr)
IS (1) IS6318A (fr)
MA (1) MA26826A1 (fr)
MX (1) MXPA02003484A (fr)
NO (1) NO20021625D0 (fr)
NZ (1) NZ517949A (fr)
OA (1) OA12063A (fr)
PA (1) PA8504301A1 (fr)
PE (1) PE20010708A1 (fr)
PL (1) PL357498A1 (fr)
PT (1) PT1221950E (fr)
SK (1) SK4542002A3 (fr)
TR (1) TR200200913T2 (fr)
UY (1) UY26376A1 (fr)
WO (2) WO2001024792A1 (fr)
ZA (1) ZA200202675B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003090743A1 (fr) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention et traitement de troubles somatiques fonctionnels, y-compris les troubles lies au stress
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
EP1721607A1 (fr) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Méthodes de traitement de troubles des voies urinaires inférieures avec des modulateurs des muscles lisses et des modulateurs des canaux calciques de la sous-unité alpha-2-delta
WO2004084881A1 (fr) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODES DE TRAITEMENT DE TROUBLES INTESTINAUX FONCTIONNELS UTILISANT DES MODULATEURS DE LA SOUS-UNITE $G(A)2$G(D) DES CANAUX CALCIQUES AVEC DES MODULATEURS DES MUSCLES LISSES
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
EP1543831A1 (fr) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Composition de pregabaline
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
WO2012015027A1 (fr) 2010-07-30 2012-02-02 東レ株式会社 Agent thérapeutique ou prophylactique pour douleur neuropathique
EP2621282B1 (fr) * 2010-09-28 2020-04-15 The Regents of The University of California Agonistes de gaba dans le traitement de troubles associés au syndrome métabolique et combinaisons de gaba dans le traitement ou la prophylaxie du diabète de type i
CA3131336A1 (fr) * 2019-03-26 2020-10-01 Mirja Huhtinen Formulations de pregabaline et leur utilisation
WO2022234110A1 (fr) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Dérivés d'acide gamma-aminobutyrique destinée à être utilisée en cancérothérapie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
ATE333879T1 (de) * 1996-10-07 2006-08-15 Merck Sharp & Dohme Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
WO1998024439A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des etats anxieux severes

Also Published As

Publication number Publication date
IS6318A (is) 2002-03-21
NO20021625L (no) 2002-04-05
EA200200303A1 (ru) 2002-08-29
PA8504301A1 (es) 2002-08-26
HRP20020286A2 (en) 2003-08-31
HUP0203466A2 (hu) 2003-02-28
BR0014598A (pt) 2002-06-11
UY26376A1 (es) 2000-12-29
CN1387434A (zh) 2002-12-25
NO20021625D0 (no) 2002-04-05
EA004266B1 (ru) 2004-02-26
PE20010708A1 (es) 2001-07-27
WO2001024792A1 (fr) 2001-04-12
EP1221950B1 (fr) 2004-06-16
EE200200185A (et) 2003-04-15
NZ517949A (en) 2003-08-29
GT200000166A (es) 2002-03-30
HUP0203466A3 (en) 2005-03-29
MXPA02003484A (es) 2004-09-10
AU1696201A (en) 2001-05-10
OA12063A (en) 2006-05-03
DK1221950T3 (da) 2004-09-20
CR6614A (es) 2003-12-04
EP1233766A1 (fr) 2002-08-28
BG106548A (en) 2002-12-29
AR029646A1 (es) 2003-07-10
DE60011650T2 (de) 2005-07-14
ZA200202675B (en) 2003-04-15
ATE269072T1 (de) 2004-07-15
AP2002002501A0 (en) 2002-06-30
WO2001024792A9 (fr) 2002-09-06
PT1221950E (pt) 2004-08-31
CZ20021116A3 (cs) 2003-05-14
AU7663300A (en) 2001-05-10
JP2003510356A (ja) 2003-03-18
CA2385930A1 (fr) 2001-04-12
IL148965A0 (en) 2002-11-10
CO5280195A1 (es) 2003-05-30
PL357498A1 (en) 2004-07-26
DE60011650D1 (de) 2004-07-22
EP1221950A1 (fr) 2002-07-17
JP2003510355A (ja) 2003-03-18
SK4542002A3 (en) 2003-09-11
KR20020060192A (ko) 2002-07-16
ES2220542T3 (es) 2004-12-16
TR200200913T2 (tr) 2002-09-23
WO2001024791A1 (fr) 2001-04-12

Similar Documents

Publication Publication Date Title
MA26826A1 (fr) Combinaisons synergiques d'un antagoniste recepteur de nk1 et d'un analogue structurel de gaba.
NO983001D0 (no) Vitronectin-reseptor-antagonister
NO983003D0 (no) Vitronectin-reseptor-antagonister
NO983002D0 (no) Vitronectin-reseptor-antagonister
NO965608D0 (no) Vitronectin-reseptor-antagonister
NO991590D0 (no) Vitronektin reseptor antagonister
FR09C0028I2 (fr) ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6
NO20010835D0 (no) NÕlløse injektorer
EP1543034A4 (fr) Traitement et prevention a l'aide d'agents fixant 4-1bb
DK0907364T3 (da) Farmaceutiske præparater med langvarig frigivelse indeholdende et dibenzothiazepinderivat
NO993350D0 (no) Vitronectin-reseptor-antagonister
ATE321784T1 (de) Pthrp analogen
DE69430699D1 (de) Medikamente abgebende stents
FI951300A7 (fi) Alfutsosiinihydrokloridin hitaan vapautumisen galeenisia muotoja
NO20001407D0 (no) Vitronectin-reseptor-antagonister
ITMI940039A0 (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
FR2772272B1 (fr) Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
BR9408265A (pt) Antagonistas de receptor de c5a não tendo substancialmente nenhuma atividade de antagonista
EE9800165A (et) Parendatud toimega LHRH antagonistid
DE69422175D1 (de) Sanitäre sprühvorrichtung für klosettschüssel
EP0781133A4 (fr) Antagonistes du recepteur de fibrinogene
DK1173172T3 (da) Synergistiske virkninger af amlodipin og den hydroxylerede metabolit af atorvastatin
FR2809711B1 (fr) Distributeur a organe de fixation et organe de fixation pour un tel distributeur
FR2763809B1 (fr) Forme helicoidale constituant un support de bille
ITMI911075U1 (it) Struttura di ancoraggio per protesi odontoiatriche su impianti endossei